Canada markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.81+0.15 (+1.29%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close11.66
Open12.00
Bid11.59 x 1300
Ask12.32 x 1000
Day's Range11.39 - 12.61
52 Week Range11.37 - 19.84
Volume4,092,598
Avg. Volume506,090
Market Cap2.827B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-8.62
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.50
  • Simply Wall St.

    Insiders who bought this year lost US$94k as Lyell Immunopharma, Inc. (NASDAQ:LYEL) sheds US$1.2b in value

    Insiders who acquired US$300k worth of Lyell Immunopharma, Inc.'s ( NASDAQ:LYEL ) stock at an average price of US$17.00...

  • GlobeNewswire

    Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15, at 2:00 PM ET. A live webcast of the fireside chat can be accessed through the investor r

  • GlobeNewswire

    Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights

    Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trialsCash, cash equivalents and marketable securities of $974.8 million as of June 30, 2021 includes $391.8 million in net proceeds from initial public offering SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported